NDAORALPOWDERPriority Review
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is hiv protease inhibitors [moa]. Approved for hiv infection. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral HIV protease inhibitor and potent cytochrome P450 3A inhibitor used to treat HIV infection, hepatitis C co-infection, pulmonary arterial hypertension, and other conditions. It works by blocking HIV protease enzyme, preventing viral replication, and is frequently used as a booster agent to enhance other antiretroviral medications. The drug is indicated for multiple therapeutic areas beyond HIV due to its pharmacokinetic enhancement properties.
$0.753MPart D
PeakStable
Product is at peak lifecycle with modest Part D utilization; small commercial team focused on maintaining market position in HIV and specialty indications.
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications (1)
Clinical Trials (20)
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
18 enrolled
HIV Infections
Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women
32 enrolled
HIV InfectionsPregnancy
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
100 enrolled
HIV Infections
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
18 enrolled
HIV InfectionsTuberculosis
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.